Holen Sie sich die Stockscreener-App
1.765
4.44%
0.075
Schlusskurs vom Vortag:
$1.69
Offen:
$1.74
24-Stunden-Volumen:
11,492
Relative Volume:
0.02
Marktkapitalisierung:
$147.93M
Einnahmen:
$47.04M
Nettoeinkommen (Verlust:
$-63.98M
KGV:
-2.1887
EPS:
-0.8064
Netto-Cashflow:
$-34.39M
1W Leistung:
-1.12%
1M Leistung:
-13.90%
6M Leistung:
-17.91%
1J Leistung:
-32.38%
1-Tages-Spanne:
$1.74
$1.77
1-Wochen-Bereich:
$1.60
$1.8007
52-Wochen-Spanne:
$1.29
$3.5107
Innate Pharma Adr Stock (IPHA) Company Profile
Firmenname
Innate Pharma Adr
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie IPHA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IPHA
Innate Pharma Adr
|
1.765 | 147.93M | 47.04M | -63.98M | -34.39M | -0.8064 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Innate Pharma Adr Stock (IPHA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2021-09-03 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2020-12-15 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2020-11-24 | Eingeleitet | Goldman | Neutral |
Innate Pharma Adr Aktie (IPHA) Neueste Nachrichten
Innate Pharma shares retain Buy rating on long-term strategy - Investing.com
Nebius Group N.V (NASDAQ: NBIS)’s Upward Trend Continues - Stocks Register
Earnings call: Innate Pharma Q3 2024 results highlight oncology pipeline - Investing.com
Earnings call: Innate Pharma focuses on advancing cancer therapies - Investing.com
Earnings call: Innate Pharma focuses on advancing cancer therapies By Investing.com - Investing.com UK
Earnings call: Innate Pharma reports progress in drug development - Investing.com India
Earnings call: Innate Pharma reports progress in oncology pipeline - Investing.com
Contrast Security Introduces Application Detection and Response (ADR) to Identify and Block Attacks and Zero Days on Applications in Production - Business Wire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday - InvestorPlace
All You Need to Know About Innate Pharma (IPHA) Rating Upgrade to Buy - Yahoo Finance
symbol__ Stock Quote Price and Forecast - CNN
Clovis Oncology Files for Chapter 11 Protection and Enters into Agreement to Sell FAP-2286 - Business Wire
Innate Pharma Gets $50 Million From AstraZeneca as Monalizumab Phase 3 Lung Cancer Trial Begins - Equities News
IPHA stock surges on upcoming presentation for AstraZeneca-partnered asset - Seeking Alpha
The Daily Biotech Pulse: Acorda Surges As Point72 Hikes Stake, Novan Sinks On Failed Study, Illumina-Pac Bio Terminate Merger - Yahoo Finance
Finanzdaten der Innate Pharma Adr-Aktie (IPHA)
Umsatz
Nettogewinn
Free Cashflow
ENV
4.81%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):